A Phase 1a/1b Study of LY3321367, an Anti-TIM-3 Antibody, Administered Alone or in Combination With LY3300054, an Anti-PD-L1 Antibody, in Advanced Relapsed/Refractory Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2019
At a glance
- Drugs LY 3321367 (Primary) ; LY 3300054
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly
- 29 Oct 2018 Planned number of patients changed from 172 to 196.
- 20 Apr 2017 Status changed from not yet recruiting to recruiting.
- 07 Apr 2017 New trial record